Palivizumab in congenital heart disease: Should international guidelines be revised?

Joseph M. Geskey, Neal J. Thomas, Gretchen L. Brummel

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Palivizumab has reduced the incidence of respiratory syncytial virus hospitalization in infants and children with congenital heart disease by 45%. Although the mortality rate of children with congenital heart disease hospitalized with respiratory syncytial virus infection has declined from 37% to ∼ 3% over the past 3 decades, palivizumab has not been shown to improve mortality. There has been considerable controversy over the cost-effectiveness of administering palivizumab according to international guidelines, including children with congenital heart disease. In particular, the number of children that need to be treated with palivizumab to prevent one respiratory syncytial virus hospitalization increases dramatically in children > 12 months of age. As a result, the authors recommend that countries re-examine their recommendations for providing palivizumab up to age 24 months in children with congenital heart disease.

Original languageEnglish (US)
Pages (from-to)1615-1620
Number of pages6
JournalExpert Opinion on Biological Therapy
Volume7
Issue number11
DOIs
StatePublished - Nov 1 2007

Fingerprint

Heart Diseases
Guidelines
Viruses
Respiratory Syncytial Viruses
Hospitalization
Respiratory Syncytial Virus Infections
Cost effectiveness
Mortality
Cost-Benefit Analysis
Palivizumab
Incidence

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

@article{8e1cda1cf0cd45c39186c27e9ad7d41d,
title = "Palivizumab in congenital heart disease: Should international guidelines be revised?",
abstract = "Palivizumab has reduced the incidence of respiratory syncytial virus hospitalization in infants and children with congenital heart disease by 45{\%}. Although the mortality rate of children with congenital heart disease hospitalized with respiratory syncytial virus infection has declined from 37{\%} to ∼ 3{\%} over the past 3 decades, palivizumab has not been shown to improve mortality. There has been considerable controversy over the cost-effectiveness of administering palivizumab according to international guidelines, including children with congenital heart disease. In particular, the number of children that need to be treated with palivizumab to prevent one respiratory syncytial virus hospitalization increases dramatically in children > 12 months of age. As a result, the authors recommend that countries re-examine their recommendations for providing palivizumab up to age 24 months in children with congenital heart disease.",
author = "Geskey, {Joseph M.} and Thomas, {Neal J.} and Brummel, {Gretchen L.}",
year = "2007",
month = "11",
day = "1",
doi = "10.1517/14712598.7.11.1615",
language = "English (US)",
volume = "7",
pages = "1615--1620",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "11",

}

Palivizumab in congenital heart disease : Should international guidelines be revised? / Geskey, Joseph M.; Thomas, Neal J.; Brummel, Gretchen L.

In: Expert Opinion on Biological Therapy, Vol. 7, No. 11, 01.11.2007, p. 1615-1620.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Palivizumab in congenital heart disease

T2 - Should international guidelines be revised?

AU - Geskey, Joseph M.

AU - Thomas, Neal J.

AU - Brummel, Gretchen L.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Palivizumab has reduced the incidence of respiratory syncytial virus hospitalization in infants and children with congenital heart disease by 45%. Although the mortality rate of children with congenital heart disease hospitalized with respiratory syncytial virus infection has declined from 37% to ∼ 3% over the past 3 decades, palivizumab has not been shown to improve mortality. There has been considerable controversy over the cost-effectiveness of administering palivizumab according to international guidelines, including children with congenital heart disease. In particular, the number of children that need to be treated with palivizumab to prevent one respiratory syncytial virus hospitalization increases dramatically in children > 12 months of age. As a result, the authors recommend that countries re-examine their recommendations for providing palivizumab up to age 24 months in children with congenital heart disease.

AB - Palivizumab has reduced the incidence of respiratory syncytial virus hospitalization in infants and children with congenital heart disease by 45%. Although the mortality rate of children with congenital heart disease hospitalized with respiratory syncytial virus infection has declined from 37% to ∼ 3% over the past 3 decades, palivizumab has not been shown to improve mortality. There has been considerable controversy over the cost-effectiveness of administering palivizumab according to international guidelines, including children with congenital heart disease. In particular, the number of children that need to be treated with palivizumab to prevent one respiratory syncytial virus hospitalization increases dramatically in children > 12 months of age. As a result, the authors recommend that countries re-examine their recommendations for providing palivizumab up to age 24 months in children with congenital heart disease.

UR - http://www.scopus.com/inward/record.url?scp=36049004863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36049004863&partnerID=8YFLogxK

U2 - 10.1517/14712598.7.11.1615

DO - 10.1517/14712598.7.11.1615

M3 - Review article

C2 - 17961086

AN - SCOPUS:36049004863

VL - 7

SP - 1615

EP - 1620

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 11

ER -